Advertisement
New Zealand markets close in 32 minutes
  • NZX 50

    11,764.53
    -7.28 (-0.06%)
     
  • NZD/USD

    0.6126
    +0.0005 (+0.07%)
     
  • NZD/EUR

    0.5714
    +0.0000 (+0.00%)
     
  • ALL ORDS

    8,023.30
    +11.20 (+0.14%)
     
  • ASX 200

    7,782.30
    +12.90 (+0.17%)
     
  • OIL

    82.34
    +0.17 (+0.21%)
     
  • GOLD

    2,375.10
    +6.10 (+0.26%)
     
  • NASDAQ

    19,752.30
    -156.56 (-0.79%)
     
  • FTSE

    8,272.46
    +67.35 (+0.82%)
     
  • Dow Jones

    39,134.76
    +299.90 (+0.77%)
     
  • DAX

    18,254.18
    +186.27 (+1.03%)
     
  • Hang Seng

    18,021.56
    -313.76 (-1.71%)
     
  • NIKKEI 225

    38,599.27
    -33.75 (-0.09%)
     
  • NZD/JPY

    97.3060
    +0.0860 (+0.09%)
     

BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update.

BioLife Solutions New Logo 2021 (PRNewsfoto/BioLife Solutions, Inc.)
BioLife Solutions New Logo 2021 (PRNewsfoto/BioLife Solutions, Inc.)

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-877-346-6112 or 1-848-280-6350 for international callers. A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days.

About BioLife Solutions
BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.

ADVERTISEMENT

Media & Investor Relations

At the Company
Troy Wichterman 
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-to-report-first-quarter-2024-financial-results-and-business-update-on-may-9-2024-302132232.html

SOURCE BioLife Solutions, Inc.